docwirenews.com
Cure8 news brief
Ustekinumab Dose Intensification Safe in Inflammatory Bowel Disease Cohort | AGA
Medications
Ustekinumab
IL-12/23 inhibitor
Fecal calprotectin
Remission
Clinical study
Adult patients
Clinicians
Why This Matters
Shortening ustekinumab dosing intervals raised drug levels and was associated with high rates of steroid-free clinical remission in this small prospective IBD cohort, offering a practical option for patients who lose response to standard maintenance dosing.
Who Should Pay Attention
Adults with Crohn's disease or ulcerative colitis on ustekinumab who have loss of response; gastroenterologists and clinicians managing biologic therapy; researchers interested in dosing strategies.
Study Snapshot
Story typeResearch news
Evidence typeClinical study
Source depthFull source text
What To Know
This was a small prospective study (19 patients) assessing empiric ustekinumab dose intensification to q6w or q4w for secondary loss of response. The main outcome was steroid-free clinical remission after the third intensified dose; about 71–75% of patients achieved that endpoint and >80% had a clinical response.
Serum ustekinumab concentrations increased after intensification while fecal calprotectin improvements were more modest. No new safety signals or therapy discontinuations due to adverse events were reported.
Clinicians may view q6w as an intermediate step before q4w intensification when addressing pharmacokinetic-related loss of response, but individual decisions should consider prior treatment history and monitoring.
Keep In Mind
This is a small prospective cohort (19 patients) rather than a randomized trial; fecal calprotectin improvements were modest despite clinical gains. The report links to a Gastro Hep Advances publication for full study details.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical study
Article type assigned from Cure8 classification; confirm details in the original source.
Publicationdocwirenews.com
Indexed viaGoogle News
Source typeWeb article
PublishedOct 1, 2026, 10:04 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Prospective Evaluation of Ustekinumab Dose Intensification in Inflammatory Bowel Diseases.
Many people on ustekinumab who lose response wonder whether increasing dosing frequency helps. This prospective study suggests that empiric intensification to every 4 or 6 weeks raised drug levels and was linked with...
Ustekinumab Dose Intensification in Crohn's Disease - Docwire News
This trial directly tests common clinical strategies for managing loss of response to ustekinumab in Crohn’s disease. The findings may change whether doctors routinely escalate to 4-weekly dosing after an IV reinduction,...
Current and novel biomarkers for predicting and assessing therapeutic response in inflammatory bowel disease: a systematic review.
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...